KERX Keryx Biopharmaceuticals, Inc. gains 20% Jul 17, 2017

Posted By: Rajesh Srivastava - Monday, July 17, 2017

Share

& Comment

Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with renal disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis. The company has licensing and collaboration agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Auryxia in Japan. It also has a license agreement with Panion & BF Biotech, Inc. for the development and marketing of ferric citrate. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts. http://www.priceseries.com/trade/KERX-Keryx-Biopharmaceuticals-Inc-stock-gains-20-percent-a-Trade-Record-by-priceSeries-2017062120170717.html

About Rajesh Srivastava

Techism is an online Publication that complies Bizarre, Odd, Strange, Out of box facts about the stuff going around in the world which you may find hard to believe and understand. The Main Purpose of this site is to bring reality with a taste of entertainment

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Copyright © priceSeries Daily Results™ is a registered trademark.

Designed by Templateism. Hosted on Blogger Platform.